{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(4)"],"submitter":["Tardif JC"],"pubmed_abstract":["<h4>Background</h4>Dalcetrapib effects on cardiovascular outcomes are determined by adenylate cyclase 9 gene polymorphisms. Our aim was to determine whether these clinical end point results are also associated with changes in reverse cholesterol transport and inflammation.<h4>Methods and results</h4>Participants of the dal-OUTCOMES and dal-PLAQUE-2 trials were randomly assigned to receive dalcetrapib or placebo in addition to standard care. High-sensitivity C-reactive protein was measured at baseline and at end of study in 5243 patients from dal-OUTCOMES also genotyped for the rs1967309 polymorphism in adenylate cyclase 9. Cholesterol efflux capacity of high-density lipoproteins from J774 macrophages after cAMP stimulation was determined at baseline and 12 months in 171 genotyped patients "],"journal":["Circulation. Cardiovascular genetics"],"pagination":["340-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4982759"],"repository":["biostudies-literature"],"pubmed_title":["Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes."],"pmcid":["PMC4982759"],"pubmed_authors":["Feroz Zada Y","Brodeur M","Rheaume E","Boule M","Fouodjio R","L'Allier PL","Alem S","Dube MP","Rhainds D","Gregoire JC","Mongrain I","Schwartz GG","Provost S","Guertin MC","Ibrahim R","Tardif JC","Olsson AG"],"additional_accession":[]},"is_claimable":false,"name":"Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.","description":"<h4>Background</h4>Dalcetrapib effects on cardiovascular outcomes are determined by adenylate cyclase 9 gene polymorphisms. Our aim was to determine whether these clinical end point results are also associated with changes in reverse cholesterol transport and inflammation.<h4>Methods and results</h4>Participants of the dal-OUTCOMES and dal-PLAQUE-2 trials were randomly assigned to receive dalcetrapib or placebo in addition to standard care. High-sensitivity C-reactive protein was measured at baseline and at end of study in 5243 patients from dal-OUTCOMES also genotyped for the rs1967309 polymorphism in adenylate cyclase 9. Cholesterol efflux capacity of high-density lipoproteins from J774 macrophages after cAMP stimulation was determined at baseline and 12 months in 171 genotyped patients ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Aug","modification":"2026-06-16T04:56:25.918Z","creation":"2019-03-27T02:20:31Z"},"accession":"S-EPMC4982759","cross_references":{"pubmed":["27418594"],"doi":["10.1161/CIRCGENETICS.116.001405"]}}